Regenicin, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGIN research report →
Companywww.regenicin.com
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers.
- CEO
- Randall E. McCoy
- IPO
- 2009
- Employees
- 3
- HQ
- Little Falls, NJ, US
Price Chart
Valuation
- Market Cap
- $15.35K
- P/E
- -0.02
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 11.88%
- ROIC
- 12.13%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-639,000 · 4.71%
- EPS
- $-0.00 · 6.25%
- Op Income
- $-601,000
- FCF YoY
- -13.21%
Performance & Tape
- 52W High
- $0.75
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.27
- Avg Volume
- 50.18K
Get TickerSpark's AI analysis on RGIN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RGIN Coverage
We haven't published any research on RGIN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RGIN Report →